Publication | Closed Access

Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA

HepatologyBiliary TractBiliary CancerLiver PhysiologyPhysiologyGastroenterologyPathologyLong-term OutcomeBiochemical ResponsesBiliary DisorderLiver DiseasePrimary Biliary CirrhosisAsymptomatic PatientsLiverMedicineCirrhosisAutoimmune Liver DiseaseHealth Sciences